Showing 1 - 10 of 328
and the Task Force report (Pronab Sen) on pricing are both available on: http …
Persistent link: https://www.econbiz.de/10005696014
How does innovation impact on development? How, and under what conditions, do entrepreneurs in developing countries innovate? And what can be done to support innovation by entrepreneurs in developing countries? This policy brief addresses these questions and explains the relationship between...
Persistent link: https://www.econbiz.de/10009323949
Written comments on the issues raised for consultation may please be furnished to Principal Advisor (FN), TRAI by 30th January, 2009. The comments may be sent in writing and also preferably be sent in electronic form (E-mail: traifn@yahoo.co.in or arvindtrai@gmail.com).
Persistent link: https://www.econbiz.de/10005341704
Drug Policy of 1986
Persistent link: https://www.econbiz.de/10009323735
Scientific authors who pay to publish their articles in an open-access publication should be congratulated for doing so. They also should be aware that they may not be getting full open access from some publications that charge for publication under the ‘‘open access’’...
Persistent link: https://www.econbiz.de/10009386045
Modifications to Drug Policy 1986
Persistent link: https://www.econbiz.de/10009250151
Procedures for fixing of prices of bulk drugs
Persistent link: https://www.econbiz.de/10009250394
Pharmaceutical Policy of 2002 covering issues of pricing, ,marketing, size of market, quality, production, investment …
Persistent link: https://www.econbiz.de/10009250530
This paper introduces wage bargaining in the framework of Milgrom and Roberts where the workers' reservation wage is the relevant information parameter critical for entry. The authors show that entry threat signicantly distorts the wage, which in turn adversely aects the rm's ability to signal...
Persistent link: https://www.econbiz.de/10005487717
In 2002 the government had formulated a new Drug Policy, but the same could not be implemented due to litigation involving it. As a consequence, the policy of 1994 continues to be in force.The present Policy known as the National Pharmaceuticals Policy, 2005 has been necessitated due to several...
Persistent link: https://www.econbiz.de/10005487771